Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab and Olaparib in BRCA-Mutant Breast and Prostate Cancer
NCT05807126Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in breast cancer and prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days, Tumor RNA sequencing at Cycle 2 and 4 more. Planned start Mar 2024; status: withdrawn.
02
Drugs
magrolimab
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05807126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807126.